| Page 1262 | Kisaco Research
 

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides is the founder of six healthcare companies: FemTec Health, Vivante Health, EosHealth which became Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently acquired by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

 

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides is the founder of six healthcare companies: FemTec Health, Vivante Health, EosHealth which became Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently acquired by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

 

Kimon recently received the 2020 Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine.  Kimon’s newest company, FemTec Health was created in 2020 to bring together all the product and services to create a total healthcare experience for women and to tackle some of the most complex health conditions using state of the art technologies. The company has taken a multidisciplinary approach using digital therapeutics, diagnostics and discovery medicine, devices, and analytics, all taken to enhance and celebrate women’s health and to break some of the taboos associated with women’s sexual wellness.   Vivante Health, that Kimon founded in 2016 after Livongo was formed to meet the needs of people who have invisible and stigmatized diseases, starting with digestive health using new advances and innovations in digital health, telemedicine, and biometric devices. 

 

Prior to his healthcare career, Kimon led strategy for Tanox, Inc., a biotech company now part of Genentech, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK building the pre-clinical services for a new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kimon was on the National Medical Board of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was a Research Career Development Awardee of the National Institutes of Health, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 60 patents. He has a PhD in Bio-organic Chemistry from the University of California and has graduate work in business, laws, and public health.

 

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson is the Therapy Area Head for Women’s Healthcare in Bayer Pharmaceuticals. She joined Bayer in 1997 and during that time and has held a variety of commercial leadership roles in both the Pharmaceutical and Crop Science divisions in the UK and across Europe. Marion started her career in the field of Women’s Health as a nurse and midwife and is passionate about delivering innovative solutions to address the unmet medical needs of women worldwide.

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson is the Therapy Area Head for Women’s Healthcare in Bayer Pharmaceuticals. She joined Bayer in 1997 and during that time and has held a variety of commercial leadership roles in both the Pharmaceutical and Crop Science divisions in the UK and across Europe. Marion started her career in the field of Women’s Health as a nurse and midwife and is passionate about delivering innovative solutions to address the unmet medical needs of women worldwide.

 

Isabel Aznarez

Co-founder and Vice President of Biology
Stoke Therapeutics

Isabel Aznarez

Co-founder and Vice President of Biology
Stoke Therapeutics

Isabel Aznarez

Co-founder and Vice President of Biology
Stoke Therapeutics
 

Andrew Prigodich

Executive Director, R&D Operations and mRNA Scientific Planning
Pfizer

Andrew Prigodich

Executive Director, R&D Operations and mRNA Scientific Planning
Pfizer

Andrew Prigodich

Executive Director, R&D Operations and mRNA Scientific Planning
Pfizer
 

Jaspreet Khurana

Director - Platform and Discovery
Strand Therapeutics

Jaspreet Khurana

Director - Platform and Discovery
Strand Therapeutics

Jaspreet Khurana

Director - Platform and Discovery
Strand Therapeutics
 

Dushyant Varshney

CTO
Arcturus Therapeutics

Dushyant Varshney

CTO
Arcturus Therapeutics

Dushyant Varshney

CTO
Arcturus Therapeutics
 

Greg Fiore

Co-founder, President & CEO
Exacis Biotherapeutics

Greg Fiore

Co-founder, President & CEO
Exacis Biotherapeutics

Greg Fiore

Co-founder, President & CEO
Exacis Biotherapeutics

The ability to maintain healthy, positive, fair, and ethical relationships is critical to long-term success. Social factors are difficult to quantify but their significance will intensify in years to come and it is imperative to plan for them.

  • Determining which definitions to use and how to identify social risk categories
  • Assessing the social risks posed by existing risk categories
  • How is reputational risk tied to social risk and what are the differences?
  • Finding the right metrics for measurement and putting a number on social risk
Social Risk
Industry & Investment

Author:

Olga Puntus

Environmental and Social Risk Management Lead
Wells Fargo

As Head of Environmental and Social Risk Management (ESRM) team, I lead Wells Fargo’s efforts to understand customers’ E&S impact and performance, and manage E&S risks across the enterprise. ESRM team also engages with key external stakeholders to understand their perspectives about the industries Wells Fargo supports, and identify solutions to pressing and emerging E&S issues.
The ESRM function provides lines-of-business the clarity and tools they need to make informed decisions when growing relationships in sensitive industries. The ESRM approach also helps the corporation more effectively manage business and credit, strategic and reputational risks to Wells Fargo, while at the same time allow it to deeper understand customers’ operations and long-term viability. We help the company protect people, communities and the environment.
Prior to joining Wells Fargo, I spent 14 years at the International Finance Corporation (IFC) conducting global E&S risk management, due diligence, supervision, and audit in the infrastructure, apparel, manufacturing, oil and gas, mining, and health and education sectors. At IFC, I worked in a number of regions, including Europe, Central Asia, Northern Africa, Middle East, Central and Southern Americas. I hold an MS in Environmental Science and Sustainability Management from Columbia University in New York; Masters of Law from Humboldt University in Berlin, Germany; and the equivalent of a JD from Belarusian State University in the Republic of Belarus. I am fluent in English, Russian, German, and Spanish. I am a certified yoga teacher and mindfulness practitioner. For fun I travel the world and practice circus arts. I have a daughter who is a joy and light of my life.

Olga Puntus

Environmental and Social Risk Management Lead
Wells Fargo

As Head of Environmental and Social Risk Management (ESRM) team, I lead Wells Fargo’s efforts to understand customers’ E&S impact and performance, and manage E&S risks across the enterprise. ESRM team also engages with key external stakeholders to understand their perspectives about the industries Wells Fargo supports, and identify solutions to pressing and emerging E&S issues.
The ESRM function provides lines-of-business the clarity and tools they need to make informed decisions when growing relationships in sensitive industries. The ESRM approach also helps the corporation more effectively manage business and credit, strategic and reputational risks to Wells Fargo, while at the same time allow it to deeper understand customers’ operations and long-term viability. We help the company protect people, communities and the environment.
Prior to joining Wells Fargo, I spent 14 years at the International Finance Corporation (IFC) conducting global E&S risk management, due diligence, supervision, and audit in the infrastructure, apparel, manufacturing, oil and gas, mining, and health and education sectors. At IFC, I worked in a number of regions, including Europe, Central Asia, Northern Africa, Middle East, Central and Southern Americas. I hold an MS in Environmental Science and Sustainability Management from Columbia University in New York; Masters of Law from Humboldt University in Berlin, Germany; and the equivalent of a JD from Belarusian State University in the Republic of Belarus. I am fluent in English, Russian, German, and Spanish. I am a certified yoga teacher and mindfulness practitioner. For fun I travel the world and practice circus arts. I have a daughter who is a joy and light of my life.

While physical risks from climate change have been discussed for many years, transition risks are a relatively new category. As companies disclose more information relating to climate change, financial firms will be able to make more informed decisions.

  • How to identify transition risk stemming from business strategy and ESG commitments
  • Determining transition risk stemming from physical risks
  • What does net zero really mean for the balance sheet?

Author:

Chandra Khandrika

Director, Internal Audit Model Risk Management
Citi

Chandra Sekhar Khandrika is Head of IA Model risk management at Citi Bank. He has 20 years of industry experience in Risk and Control areas including Risk Management, Independent valuation, and audit at global Investment banks. His interests are in the intersection of financial risk and climate risks. He is interests in the nexus of climate risk regulatory landscape and low carbon economy transition. Specifically, embedding climate risk management framework, stress testing, scenario analysis and disclosures. Low carbon economy transition and adaptation and mitigation strategies leveraging clean technologies.

Chandra Khandrika

Director, Internal Audit Model Risk Management
Citi

Chandra Sekhar Khandrika is Head of IA Model risk management at Citi Bank. He has 20 years of industry experience in Risk and Control areas including Risk Management, Independent valuation, and audit at global Investment banks. His interests are in the intersection of financial risk and climate risks. He is interests in the nexus of climate risk regulatory landscape and low carbon economy transition. Specifically, embedding climate risk management framework, stress testing, scenario analysis and disclosures. Low carbon economy transition and adaptation and mitigation strategies leveraging clean technologies.

66% of major global companies have at least one asset at high risk of physical risk under the high impact climate change scenario in 2050.

  • Determining the physical risks facing portfolios
  • Correctly assessing portfolio geography and asset composition
  • Reviewing which risks matter and why
  • Which parameters should be modeled and how do you use them effectively?
  • Utilizing critical insight from the Task Force on Climate-related Financial Disclosures (TCFD)
ESG Risk

Author:

Rhea Rajwani

Director, Head of US Model Risk Governance and Controls
TD Bank

Rhea Rajwani heads the Model Risk Governance and Controls portfolio for TD Bank in the US. She has worked with the Bank since 2006 on both sides of the border – Canada and the US, in Finance & Risk Management. In addition to her work past few years in model risk governance, her areas of expertise include financial modeling, efficiency planning, resolution and recovery planning primarily focused on strategy and liquidity management, model validations, management and regulatory reporting and investor relations. Prior to joining TD, Rhea has worked at the Bank of India in Planning and Forecasting and ICICI Bank where she was responsible for Capital Planning and Regulatory filings including her work on filings with the SEC in the US and as a representative from the Bank to the working committee for Basel supervision and reporting at the Reserve Bank of India. Rhea has a Masters degree in Business, Bachelors degree in Financial Accounting & Auditing, completed the Canadian Securities Course, is a Certified Associate of the Indian Institute of Bankers, passed the CFA level II exams and has several technology certifications to her credit.     

Rhea Rajwani

Director, Head of US Model Risk Governance and Controls
TD Bank

Rhea Rajwani heads the Model Risk Governance and Controls portfolio for TD Bank in the US. She has worked with the Bank since 2006 on both sides of the border – Canada and the US, in Finance & Risk Management. In addition to her work past few years in model risk governance, her areas of expertise include financial modeling, efficiency planning, resolution and recovery planning primarily focused on strategy and liquidity management, model validations, management and regulatory reporting and investor relations. Prior to joining TD, Rhea has worked at the Bank of India in Planning and Forecasting and ICICI Bank where she was responsible for Capital Planning and Regulatory filings including her work on filings with the SEC in the US and as a representative from the Bank to the working committee for Basel supervision and reporting at the Reserve Bank of India. Rhea has a Masters degree in Business, Bachelors degree in Financial Accounting & Auditing, completed the Canadian Securities Course, is a Certified Associate of the Indian Institute of Bankers, passed the CFA level II exams and has several technology certifications to her credit.